Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab vs obinutuzumab in SLE: effects on lymphocyte subsets
2024-518965-85-00Phase 4Authorised
- Sponsor
- Amsterdam University Medical Center
- Start
- Nov 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised trial in systemic lupus erythematosus (SLE) comparing Rituximab arm with Obinutuzumab arm (2 arms). Primary endpoints: B-cell depletion in peripheral blood (CD19+) and B-cell depletion in lymph nodes (CD19+). Planned start Nov 2024; status: authorised.
02
Drugs
rituximabobinutuzumab
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on 2024-518965-85-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518965-85-00.